World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
96
Citations
36281
World Ranking
9609
National Ranking
4952

Gary J. Kelloff publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Gary J. Kelloff sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 360 publications — 30th percentile

30% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Gary J. Kelloff D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Gary J. Kelloff sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 96 D-Index — 53rd percentile

53% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Gary J. Kelloff is affiliated with the National Institutes of Health in the United States, with a research focus spanning multiple fields within biomedical science. Their work concentrates primarily on cancer genomics and diagnostics, with significant contributions to lymphoma, multiple myeloma, and molecular biology techniques.

The main fields of study represented in their research include biochemistry, genetics, and molecular biology, alongside medicine. Subfields within their work encompass molecular biology, cancer research, pathology and forensic medicine, neurology, and oncology.

Key topics covered in their publications include:

  • Cancer Genomics and Diagnostics
  • Lymphoma Diagnosis and Treatment
  • CNS Lymphoma Diagnosis and Treatment
  • Molecular Biology Techniques and Applications
  • Single-cell and Spatial Transcriptomics
  • Sarcoma Diagnosis and Treatment
  • Multiple Myeloma Research and Treatments

Selected recent papers authored or co-authored by Gary J. Kelloff highlight a range of oncology and cancer diagnostic subjects. These include:

  • Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial, 2020, Blood
  • Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration, 2021, Clinical Cancer Research
  • Challenges to Using Big Data in Cancer, 2023, Cancer Research
  • Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health, 2021, JCO Precision Oncology
  • Case Studies for Overcoming Challenges in Using Big Data in Cancer, 2023, Cancer Research

Frequent co-authors in their research include Dana E. Connors, Caroline C. Sigman, Howard R. Higley, Stacey J. Adam, and Ilan R. Kirsch. These collaborations suggest interdisciplinary teamwork on cancer research challenges.

Their research is published in notable venues such as Cancer Research, Blood, Clinical Cancer Research, JCO Precision Oncology, and The Oncologist, reflecting a focus on oncological and translational medicine.

Best Publications

  • The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis

    Gideon Steinbach;Patrick M. Lynch;Robin K S Phillips;Marina H. Wallace

  • Chemopreventive Effect of Curcumin, a Naturally Occurring Anti-Inflammatory Agent, during the Promotion/Progression Stages of Colon Cancer

    Toshihiko Kawamori;Ronald Lubet;Vernon E. Steele;Gary J. Kelloff

  • Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

    Gary J. Kelloff;John M. Hoffman;Bruce Johnson;Howard I. Scher

  • I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

    AD Barker;CC Sigman;GJ Kelloff;NM Hylton

  • The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.

    Russell F. Jacoby;Karen Seibert;Carolyn E. Cole;Gary Kelloff

  • Chemoprevention of Colon Cancer by Specific Cyclooxygenase-2 Inhibitor, Celecoxib, Administered during Different Stages of Carcinogenesis

    Bandaru S. Reddy;Yoshinobu Hirose;Ronald Lubet;Vernon Steele

  • Progress in Cancer chemoprevention : Development of diet-derived chemopreventive agents

    Gary J. Kelloff;James A. Crowell;Vernon E. Steele;Ronald A. Lubet

  • Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review.

    Charles W. Boone;Gary J. Kelloff;Winfred E. Malone

  • Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial

    Frank L. Meyskens;Christine E. McLaren;Daniel Pelot;Sharon Fujikawa-Brooks

  • Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia

    Joyce A. O’Shaughnessy;Gary J. Kelloff;Gary B. Gordon;Andrew J. Dannenberg

  • Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent.

    Chinthalapally V. Rao;Abraham Rivenson;Barbara Simi;Edith Zang

  • A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.

    R.K.S. Phillips;Marina Wallace;P.M. Lynch;E. Hawk

  • Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.

    Susan M. Fischer;Herng-Hsang Lo;Gary B. Gordon;Karen Seibert

  • Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.

    Donald A. Berry;Shouhao Zhou;Howard Higley;Lata Mukundan

  • Modulation of Apoptosis by Sulindac, Curcumin, Phenylethyl-3-methylcaffeate, and 6-Phenylhexyl Isothiocyanate: Apoptotic Index as a Biomarker in Colon Cancer Chemoprevention and Promotion

    Hanan S. Samaha;Gary J. Kelloff;Vernon Steele;Chinthalapally V. Rao

  • Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development.

    Bandaru S. Reddy;Hiroshi Maruyama;Gary Kelloff

  • Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats

    Bandaru S. Reddy;Chinthalapally V. Rao;Abraham Rivenson;Gary Kelloff

  • Screening of Potential Chemopreventive Agents Using Biochemical Markers of Carcinogenesis

    Sheela Sharma;Jill D. Stutzman;Gary J. Kelloff;Vernon E. Steele

  • Perspectives on cancer chemoprevention research and drug development.

    Gary J. Kelloff

  • Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam

    Russell F. Jacoby;David J. Marshall;Michael A. Newton;Kristian Novakovic

Frequent Co-Authors

Vernon E. Steele
Vernon E. Steele National Institutes of Health
Ronald A. Lubet
Ronald A. Lubet National Institutes of Health
Bandaru S. Reddy
Bandaru S. Reddy Rutgers, The State University of New Jersey
Raymond V. Gilden
Raymond V. Gilden National Institutes of Health
Ming You
Ming You Medical College of Wisconsin
Chinthalapally V. Rao
Chinthalapally V. Rao University of Oklahoma Health Sciences Center
Gary D. Stoner
Gary D. Stoner The Ohio State University
Robert J. Huebner
Robert J. Huebner National Institutes of Health
Levy Kopelovich
Levy Kopelovich Cornell University
Scott M. Lippman
Scott M. Lippman University of California, San Diego

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine opens up various alternative educational options and related healthcare paths online. Many students opt for specialized programs like financial aid for medical billing and coding online classes. These programs provide a flexible and affordable way to enter the rapidly growing health information sector.

If you’re interested in nursing, there are accessible routes such as an lpn program without teas test. These pathways allow you to start your nursing journey without the hurdle of entrance exams, making it easier to begin your career.

For those aiming for leadership roles, consider a health administration degree. Earning this qualification online can quickly prepare you for management positions in hospitals, clinics, or other healthcare organizations.

Registered nurses looking to advance their qualifications might explore adn to msn bridge programs. These programs are designed to help ADN-prepared nurses earn a master’s degree efficiently, opening opportunities in advanced practice or administration.

Best Scientists Citing Gary J. Kelloff

Trending Scientists

Recently Published Articles